ClinicalTrials.gg
CompletedNCT03816696Updated Mar 19, 2020Results posted

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

A Phase 1 interventional study of GSK3640254 and DTG in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-19.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing GSK3640254 in HIV Infections — none open to participants now, none under way, none of them phase 3. GSK3640254 · HIV Infections.

Enrollment
11th of 15
16 · median 34
Started
2019
with 4 others
Phase 1
12 of 15
none open now
Registered
4th of 15
by date
Lead sponsor
15 of 15
ViiV Healthcare

Among the 15 studies testing GSK3640254 in HIV Infections, this one is the 11th largest by enrollment, is one of 5 that started in 2019, is one of 12 in phase 1, and was the 4th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 15 studies testing GSK3640254 in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About GSK3640254

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing GSK3640254 in HIV Infections as a file.
02

Study summary

This is an open-label, single-sequence, two-way drug interaction study to investigate the PK, safety and tolerability of GSK3640254 and DTG when administered alone or in combination in healthy subjects. Treatment of human immunodeficiency virus (HIV) infection frequently involves combination therapy. Data from this study will contribute to dosing recommendations when GSK3640254 and DTG are given in combination. The study will consist of a Screening period and 3 sequential treatment periods. Subjects will be administered DTG 50 milligrams (mg) once daily (QD) in Period 1 followed by GSK3640254 200 mg QD in Period 2. There will be a washout period of 4 days between Periods 1 and 2. In Period 3, subjects will be co-administered DTG 50 mg QD and GSK3640254 200 mg QD. The total duration of the study will be approximately 55 days, including Screening.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • GSK3640254, dolutegravir, healthy subjects, two-way interaction, HIV
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 18 to 55 years of age inclusive, at the time of signing the .
  • Subjects who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and ).
  • Body weight >=50 kilograms (kg) (110 pounds [lbs]) for men and >=45.0 kg (99 lbs) for women and within the range 18.5 to 31.0 kilograms per square meter (kg/m\^2) (inclusive).
  • Male or female subjects can participate. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and not a woman of (WOCBP).
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.

Exclusion criteria

Exclusion Criteria:

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • A pre-existing condition interfering with normal gastrointestinal (GI) anatomy or motility (e.g., gastroesophageal reflux disease, gastric ulcers, gastritis), hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs or render the subject unable to take oral study intervention.
  • Any history of significant underlying psychiatric disorder, including but not limited to schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder.
  • Any history of major depressive disorder with or without suicidal features, or anxiety disorders, that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6 months) outpatient treatment. Subjects with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (\<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Medical Monitor.
  • Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the investigator (with or without psychiatric evaluation), could interfere with the subject's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the subject.
  • Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long syndrome.
  • Presence of surface antigen (HBsAg) at Screening or within 3 months prior to starting study intervention.
  • Positive antibody test result at Screening or within 3 months prior to starting study intervention and positive on reflex to Hepatitis C ribonucleic acid (RNA).
  • Positive -1 and -2 antigen/antibody immunoassay at Screening.
  • >1.5 times (ULN). A single repeat of ALT is allowed within a single screening period to determine eligibility.
  • >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent).
  • Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should preclude participation in the study of an compound.
  • Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of creatine phosphokinase (CPK) and lipid abnormalities (e.g., total cholesterol, triglycerides), and ALT (described above), will exclude a subject from the study unless the investigator can provide a compelling explanation for the laboratory results and has the assent of the sponsor. A single repeat of any laboratory abnormality is allowed within a single screening period to determine eligibility.
  • A positive test result for drugs of abuse (including marijuana), alcohol, or cotinine (indicating active current smoking) at Screening or before the first dose of study intervention.
  • Unable to refrain from the use of prescription or non-prescription drugs including vitamins, herbal and dietary supplements (including St John's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication and for the duration of the study.
  • Treatment with any vaccine within 30 days prior to receiving study intervention.
  • Unwillingness to abstain from excessive consumption of any food or drink containing grapefruit and grapefruit juice, Seville oranges, blood oranges, or pomelos or their fruit juices within 7 days prior to the first dose of study intervention(s) until the end of the study.
  • Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the study intervention (whichever is longer).
  • Where participation in the study would result in donation of blood or blood products in excess of 500 milliliter (mL) within 56 days.
  • Any positive (abnormal) response confirmed by the investigator on a screening clinician- or qualified designee-administered Columbia Suicide Severity Rating Scale (C-SSRS).
  • Any significant arrhythmia or finding (e.g., prior myocardial infarction, sinoatrial pauses, bundle branch block, or conduction abnormality) which, in the opinion of the investigator or ViiV Healthcare (VH)/GlaxoSmithKline (GSK) Medical Monitor, will interfere with the safety for the individual subject.
  • Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate (males: \<45 or >100 beats per minute [bpm] and females: \<50 or >100 bpm); PR interval (\<120 or >200 milliseconds [msec]); QRS duration (\<70 or >110 msec); QTcF interval (males: >450 msec and females: >470 msec).
  • History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 units. One unit is equivalent to 8 grams of alcohol: a half-pint (equivalent to 240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spirits.
  • Regular use of tobacco- or nicotine-containing products within 3 months prior to Screening.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    DTG followed by GSK3640254 followed by DTG+GSK3640254

    Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.

    Drug: GSK3640254 · Drug: DTG

Interventions

  • GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.

  • DrugDTG

    DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.

06

What researchers measure

Primary outcomes

  1. Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic Parameter Population consisted of all participants who underwent plasma pharmacokinetic sampling and had evaluable pharmacokinetic parameters estimated.

    Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  2. Period 3: AUC(0 to Tau) of Dolutegravir for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  3. Period 1: Maximum Observed Concentration (Cmax) of Dolutegravir for Dolutegravir Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  4. Period 3: Cmax of Dolutegravir for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  5. Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir for Dolutegravir Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  6. Period 3: Ctau of Dolutegravir for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  7. Period 2: AUC(0 to Tau) of GSK3640254 for GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  8. Period 3: AUC(0 to Tau) of GSK3640254 for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  9. Period 2: Cmax of GSK3640254 for GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  10. Period 3: Cmax of GSK3640254 for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  11. Period 2: Ctau of GSK3640254 for GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  12. Period 3: Ctau of GSK3640254 for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

Secondary outcomes

  1. Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.

    Time frame: Up to Day 27

  2. Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

    Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  3. Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

    Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  4. Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

    Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  5. Period 1: Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  6. Period 2: Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  7. Period 3: Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  8. Period 1: Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  9. Period 2: Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  10. Period 3: Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  11. Period 1: Change From Baseline in Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  12. Period 2: Change From Baseline in Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  13. Period 3: Change From Baseline in Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  14. Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  15. Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  16. Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  17. Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  18. Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  19. Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  20. Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

    Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  21. Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

    Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  22. Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

    Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  23. Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  24. Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  25. Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  26. Period 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  27. Period 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  28. Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  29. Period 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  30. Period 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  31. Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  32. Period 1: Change From Baseline in Chemistry Parameters: Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  33. Period 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  34. Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  35. Period 1: Change From Baseline in Urinalysis Parameter: Specific Gravity

    Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  36. Period 2: Change From Baseline in Urinalysis Parameter: Specific Gravity

    Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  37. Period 3: Change From Baseline in Urinalysis Parameter: Specific Gravity

    Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  38. Period 1: Change From Baseline in Urinalysis Parameter: Urobilinogen

    Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  39. Period 2: Change From Baseline in Urinalysis Parameter: Urobilinogen

    Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  40. Period 3: Change From Baseline in Urinalysis Parameter: Urobilinogen

    Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  41. Period 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH)

    Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day -1) and at Day 9

  42. Period 2: Change From Baseline in Urinalysis Parameter: pH

    Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 1 Day 9) and at Day 7

  43. Period 3: Change From Baseline in Urinalysis Parameter: pH

    Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Period 2 Day 7) and at Days 4, 7 and 10

  44. Period 1: Number of Participants With Urinalysis Dipstick Results

    Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present) and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.

    Time frame: Day 9

  45. Period 2: Number of Participants With Urinalysis Dipstick Results

    Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.

    Time frame: Day 7

  46. Period 3: Number of Participants With Urinalysis Dipstick Results

    Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present)indicating proportional concentrations in the urine sample.

    Time frame: Days 4, 7 and 10

  47. Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB)

    Twelve-lead electrocardiograms (ECG) were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline, Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

  48. Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB

    Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline; Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

  49. Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB

    Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline; Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10

  50. Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

  51. Period 2: Change From Baseline in SBP and DBP

    SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

  52. Period 3: Change From Baseline in SBP and DBP

    SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  53. Period 1: Change From Baseline in Pulse Rate

    Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

  54. Period 2: Change From Baseline in Pulse Rate

    Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

  55. Period 3: Change From Baseline in Pulse Rate

    Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  56. Period 1: Change From Baseline in Respiratory Rate

    Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

  57. Period 2: Change From Baseline in Respiratory Rate

    Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

  58. Period 3: Change From Baseline in Respiratory Rate

    Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  59. Period 1: Change From Baseline in Body Temperature

    Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5

  60. Period 2: Change From Baseline in Body Temperature

    Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7

  61. Period 3: Change From Baseline in Body Temperature

    Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  62. Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

    Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

    Time frame: Day 9

  63. Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

    Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

    Time frame: Day 7

  64. Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

    Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

    Time frame: Days 4, 7 and 10

  65. Period 1: Absolute Values for Hematology Parameter: Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin.

    Time frame: Day 9

  66. Period 2: Absolute Values for Hematology Parameter: Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin.

    Time frame: Day 7

  67. Period 3: Absolute Values for Hematology Parameter: Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin.

    Time frame: Days 4, 7 and 10

  68. Period 1: Absolute Values for Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit.

    Time frame: Day 9

  69. Period 2: Absolute Values for Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit.

    Time frame: Day 7

  70. Period 3: Absolute Values for Hematology Parameter: Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit.

    Time frame: Days 4, 7 and 10

  71. Period 1: Absolute Values for Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes.

    Time frame: Day 9

  72. Period 2: Absolute Values for Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes.

    Time frame: Day 7

  73. Period 3: Absolute Values for Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes.

    Time frame: Days 4, 7 and 10

  74. Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

    Time frame: Day 9

  75. Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

    Time frame: Day 7

  76. Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

    Time frame: Days 4, 7 and 10

  77. Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

    Time frame: Day 9

  78. Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

    Time frame: Day 7

  79. Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

    Time frame: Days 4, 7 and 10

  80. Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

    Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

    Time frame: Day 9

  81. Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

    Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

    Time frame: Day 7

  82. Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

    Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

    Time frame: Days 4, 7 and 10

  83. Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

    Time frame: Day 9

  84. Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

    Time frame: Day 7

  85. Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

    Time frame: Days 4, 7 and 10

  86. Period 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

    Time frame: Day 9

  87. Period 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

    Time frame: Day 7

  88. Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

    Time frame: Days 4, 7 and 10

  89. Period 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

    Time frame: Day 9

  90. Period 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

    Time frame: Day 7

  91. Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

    Time frame: Days 4, 7 and 10

  92. Period 1: Absolute Values for Chemistry Parameters: Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

    Time frame: Day 9

  93. Period 2: Absolute Values for Chemistry Parameters: Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

    Time frame: Day 7

  94. Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

    Time frame: Days 4, 7 and 10

  95. Period 1: Absolute Values for Urinalysis Parameter: Specific Gravity

    Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

    Time frame: Day 9

  96. Period 2: Absolute Values for Urinalysis Parameter: Specific Gravity

    Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

    Time frame: Day 7

  97. Period 3: Absolute Values for Urinalysis Parameter: Specific Gravity

    Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

    Time frame: Days 4, 7 and 10

  98. Period 1: Absolute Values for Urinalysis Parameter: Urobilinogen

    Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

    Time frame: Day 9

  99. Period 2: Absolute Values for Urinalysis Parameter: Urobilinogen

    Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

    Time frame: Day 7

  100. Period 3: Absolute Values for Urinalysis Parameter: Urobilinogen

    Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

    Time frame: Days 4, 7 and 10

  101. Period 1: Absolute Values for Urinalysis Parameter: pH

    Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

    Time frame: Day 9

  102. Period 2: Absolute Values for Urinalysis Parameter: pH

    Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

    Time frame: Day 7

  103. Period 3: Absolute Values for Urinalysis Parameter: pH

    Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

    Time frame: Days 4, 7 and 10

  104. Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB

    Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

    Time frame: Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

  105. Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB

    Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

    Time frame: Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours

  106. Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB

    Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

    Time frame: Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10

  107. Period 1: Absolute Values for SBP and DBP

    SBP and DBP were measured in the semi-recumbent position with a completely automated device.

    Time frame: Days 2, 3, 4 and 5

  108. Period 2: Absolute Values for SBP and DBP

    SBP and DBP were measured in the semi-recumbent position with a completely automated device.

    Time frame: Days 2, 3, 4, 5, 6 and 7

  109. Period 3: Absolute Values for SBP and DBP

    SBP and DBP were measured in the semi-recumbent position with a completely automated device.

    Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  110. Period 1: Absolute Values for Pulse Rate

    Pulse rate was measured in the semi-recumbent position with a completely automated device.

    Time frame: Days 2, 3, 4 and 5

  111. Period 2: Absolute Values for Pulse Rate

    Pulse rate was measured in the semi-recumbent position with a completely automated device.

    Time frame: Days 2, 3, 4, 5, 6 and 7

  112. Period 3: Absolute Values for Pulse Rate

    Pulse rate was measured in the semi-recumbent position with a completely automated device.

    Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  113. Period 1: Absolute Values for Respiratory Rate

    Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Days 2, 3, 4 and 5

  114. Period 2: Absolute Values for Respiratory Rate

    Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Days 2, 3, 4, 5, 6 and 7

  115. Period 3: Absolute Values for Respiratory Rate

    Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  116. Period 1: Absolute Values for Body Temperature

    Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Days 2, 3, 4 and 5

  117. Period 2: Absolute Values for Body Temperature

    Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Days 2, 3, 4, 5, 6 and 7

  118. Period 3: Absolute Values for Body Temperature

    Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11

  119. Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 for GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  120. Period 3: Tmax of GSK3640254 for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  121. Period 2: Apparent Terminal Phase Half-life (T1/2) of GSK3640254 for GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Data could not be determined due to limited sampling points after final dosing (during elimination phase). An accurate determination of GSK3640254 half-life would require sampling up to 3 times half-life (3 \* approximately 24 hours). However sampling in Period 2 was performed up to only 24 hours post-dose.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  122. Period 3: T1/2 of GSK3640254 for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  123. Period 1: Tmax of Dolutegravir for Dolutegravir Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  124. Period 3: Tmax of Dolutegravir for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  125. Period 1: T1/2 of Dolutegravir for Dolutegravir Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

  126. Period 3: T1/2 of Dolutegravir for Dolutegravir + GSK3640254 Arm

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

    Time frame: Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose

07

Results

Posted Mar 19, 2020

Participant flow

This was an open-label, fixed-sequence, two-way drug interaction and 3-period study. Participants received treatment A- dolutegravir 50 milligram (mg) in Period 1; treatment B- GSK3640254 200 mg in Period 2 and treatment C- dolutegravir 50 mg and GSK3640254 200 mg in Period 3.

Period 1 (Up to Day 5)
Participant flow — Period 1 (Up to Day 5)
MilestoneDolutegravir/GSK3640254/Dolutegravir+GSK3640254
Started16
Completed16
Not completed0
Wash Out Period (Days 6 to 9)
Participant flow — Wash Out Period (Days 6 to 9)
MilestoneDolutegravir/GSK3640254/Dolutegravir+GSK3640254
Started16
Completed16
Not completed0
Period 2 (Up to Day 7)
Participant flow — Period 2 (Up to Day 7)
MilestoneDolutegravir/GSK3640254/Dolutegravir+GSK3640254
Started16
Completed16
Not completed0
Period 3 (Up to Day 11)
Participant flow — Period 3 (Up to Day 11)
MilestoneDolutegravir/GSK3640254/Dolutegravir+GSK3640254
Started16
Completed16
Not completed0

Outcome measures

PrimaryPeriod 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic Parameter Population consisted of all participants who underwent plasma pharmacokinetic sampling and had evaluable pharmacokinetic parameters estimated.

Time frame:
Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours* nanogram per milliliter
Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm
Hours* nanogram per milliliterDolutegravir 50 mg
Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm64627.8 ± 20.1
PrimaryPeriod 3: AUC(0 to Tau) of Dolutegravir for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours* nanogram per milliliter
Period 3: AUC(0 to Tau) of Dolutegravir for Dolutegravir + GSK3640254 Arm
Hours* nanogram per milliliterDolutegravir 50 mg + GSK3640254 200 mg
Period 3: AUC(0 to Tau) of Dolutegravir for Dolutegravir + GSK3640254 Arm75860.5 ± 22.7
PrimaryPeriod 1: Maximum Observed Concentration (Cmax) of Dolutegravir for Dolutegravir Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Period 1: Maximum Observed Concentration (Cmax) of Dolutegravir for Dolutegravir Arm
Nanogram per milliliterDolutegravir 50 mg
Period 1: Maximum Observed Concentration (Cmax) of Dolutegravir for Dolutegravir Arm4962 ± 16.5
PrimaryPeriod 3: Cmax of Dolutegravir for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Period 3: Cmax of Dolutegravir for Dolutegravir + GSK3640254 Arm
Nanogram per milliliterDolutegravir 50 mg + GSK3640254 200 mg
Period 3: Cmax of Dolutegravir for Dolutegravir + GSK3640254 Arm5408 ± 17.2
PrimaryPeriod 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir for Dolutegravir Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir for Dolutegravir Arm
Nanogram per milliliterDolutegravir 50 mg
Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of Dolutegravir for Dolutegravir Arm1373 ± 30.6
PrimaryPeriod 3: Ctau of Dolutegravir for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter
Period 3: Ctau of Dolutegravir for Dolutegravir + GSK3640254 Arm
Nanogram per milliliterDolutegravir 50 mg + GSK3640254 200 mg
Period 3: Ctau of Dolutegravir for Dolutegravir + GSK3640254 Arm1696 ± 31.1
PrimaryPeriod 2: AUC(0 to Tau) of GSK3640254 for GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours* microgram per milliliter
Period 2: AUC(0 to Tau) of GSK3640254 for GSK3640254 Arm
Hours* microgram per milliliterGSK3640254 200 mg
Period 2: AUC(0 to Tau) of GSK3640254 for GSK3640254 Arm26.72 ± 32.3
PrimaryPeriod 3: AUC(0 to Tau) of GSK3640254 for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours* microgram per milliliter
Period 3: AUC(0 to Tau) of GSK3640254 for Dolutegravir + GSK3640254 Arm
Hours* microgram per milliliterDolutegravir 50 mg + GSK3640254 200 mg
Period 3: AUC(0 to Tau) of GSK3640254 for Dolutegravir + GSK3640254 Arm27.84 ± 30.1
PrimaryPeriod 2: Cmax of GSK3640254 for GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Microgram per milliliter
Period 2: Cmax of GSK3640254 for GSK3640254 Arm
Microgram per milliliterGSK3640254 200 mg
Period 2: Cmax of GSK3640254 for GSK3640254 Arm1.676 ± 26.4
PrimaryPeriod 3: Cmax of GSK3640254 for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Microgram per milliliter
Period 3: Cmax of GSK3640254 for Dolutegravir + GSK3640254 Arm
Microgram per milliliterDolutegravir 50 mg + GSK3640254 200 mg
Period 3: Cmax of GSK3640254 for Dolutegravir + GSK3640254 Arm1.662 ± 26.8
PrimaryPeriod 2: Ctau of GSK3640254 for GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Microgram per milliliter
Period 2: Ctau of GSK3640254 for GSK3640254 Arm
Microgram per milliliterGSK3640254 200 mg
Period 2: Ctau of GSK3640254 for GSK3640254 Arm0.8583 ± 38.3
PrimaryPeriod 3: Ctau of GSK3640254 for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Microgram per milliliter
Period 3: Ctau of GSK3640254 for Dolutegravir + GSK3640254 Arm
Microgram per milliliterDolutegravir 50 mg + GSK3640254 200 mg
Period 3: Ctau of GSK3640254 for Dolutegravir + GSK3640254 Arm0.8549 ± 34.1
SecondaryNumber of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of study medication.

Time frame:
Up to Day 27
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
ParticipantsDolutegravir 50 mgGSK3640254 200 mgDolutegravir 50 mg + GSK3640254 200 mg
Non-SAEs132
SAEs000
SecondaryPeriod 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · 10^9 cells per liter
Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
10^9 cells per literDolutegravir 50 mg
Basophils-0.003 ± 0.0124
Eosinophils0.046 ± 0.1198
Lymphocytes0.013 ± 0.3793
Monocytes-0.020 ± 0.0829
Neutrophils-0.217 ± 0.6421
Platelet count-6.5 ± 21.73
SecondaryPeriod 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · 10^9 cells per liter
Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
10^9 cells per literGSK3640254 200 mg
Basophils-0.006 ± 0.0089
Eosinophils-0.026 ± 0.0810
Lymphocytes-0.154 ± 0.2718
Monocytes-0.024 ± 0.0701
Neutrophils-0.160 ± 0.3762
Platelet count-6.0 ± 30.58
SecondaryPeriod 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · 10^9 cells per liter
Period 3: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
10^9 cells per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Basophils, n=160.003 ± 0.0101
Day 7: Basophils, n=160.007 ± 0.0135
Day 10: Basophils, n=160.003 ± 0.0144
Day 4: Eosinophils, n=16-0.001 ± 0.0448
Day 7: Eosinophils, n=160.004 ± 0.0846
Day 10: Eosinophils, n=16-0.036 ± 0.0468
Day 4: Lymphocytes, n=16-0.130 ± 0.2931
Day 7: Lymphocytes, n=16-0.033 ± 0.3260
Day 10: Lymphocytes, n=16-0.117 ± 0.2628
Day 4: Monocytes, n=160.049 ± 0.1627
Day 7: Monocytes, n=160.003 ± 0.0850
Day 10: Monocytes, n=16-0.018 ± 0.0693
Day 4: Neutrophils, n=160.443 ± 1.5098
Day 7: Neutrophils, n=160.076 ± 0.5969
Day 10: Neutrophils, n=160.204 ± 0.5116
Day 4: Platelet count, n=16-4.9 ± 11.08
Day 7: Platelet count, n=15-11.5 ± 12.03
Day 10: Platelet count, n=16-5.9 ± 16.50
SecondaryPeriod 1: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Grams per liter
Period 1: Change From Baseline in Hematology Parameter: Hemoglobin
Grams per literDolutegravir 50 mg
Period 1: Change From Baseline in Hematology Parameter: Hemoglobin4.4 ± 5.97
SecondaryPeriod 2: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Grams per liter
Period 2: Change From Baseline in Hematology Parameter: Hemoglobin
Grams per literGSK3640254 200 mg
Period 2: Change From Baseline in Hematology Parameter: Hemoglobin0.1 ± 2.53
SecondaryPeriod 3: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Grams per liter
Period 3: Change From Baseline in Hematology Parameter: Hemoglobin
Grams per literDolutegravir 50 mg + GSK3640254 200 mg
Day 43.3 ± 3.00
Day 70.6 ± 3.50
Day 101.2 ± 3.69
SecondaryPeriod 1: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Proportion of red blood cells in blood
Period 1: Change From Baseline in Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodDolutegravir 50 mg
Period 1: Change From Baseline in Hematology Parameter: Hematocrit0.0178 ± 0.01988
SecondaryPeriod 2: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Proportion of red blood cells in blood
Period 2: Change From Baseline in Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodGSK3640254 200 mg
Period 2: Change From Baseline in Hematology Parameter: Hematocrit-0.0013 ± 0.00948
SecondaryPeriod 3: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Proportion of red blood cells in blood
Period 3: Change From Baseline in Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodDolutegravir 50 mg + GSK3640254 200 mg
Day 40.0035 ± 0.00794
Day 7-0.0049 ± 0.01101
Day 10-0.0041 ± 0.01402
SecondaryPeriod 1: Change From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Trillion cells per liter
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes
Trillion cells per literDolutegravir 50 mg
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes0.170 ± 0.2080
SecondaryPeriod 2: Change From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Trillion cells per liter
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes
Trillion cells per literGSK3640254 200 mg
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes0.036 ± 0.1020
SecondaryPeriod 3: Change From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Trillion cells per liter
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes
Trillion cells per literDolutegravir 50 mg + GSK3640254 200 mg
Day 40.016 ± 0.0943
Day 7-0.079 ± 0.1038
Day 10-0.054 ± 0.1540
SecondaryPeriod 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Femtoliter
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
FemtoliterDolutegravir 50 mg
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume0.63 ± 0.774
SecondaryPeriod 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Femtoliter
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
FemtoliterGSK3640254 200 mg
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume-0.86 ± 0.564
SecondaryPeriod 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Femtoliter
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
FemtoliterDolutegravir 50 mg + GSK3640254 200 mg
Day 40.40 ± 0.542
Day 70.36 ± 0.762
Day 100.05 ± 0.954
SecondaryPeriod 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Picograms
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
PicogramsDolutegravir 50 mg
Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin-0.11 ± 0.279
SecondaryPeriod 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Picograms
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
PicogramsGSK3640254 200 mg
Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin-0.17 ± 0.218
SecondaryPeriod 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Picograms
Period 3: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
PicogramsDolutegravir 50 mg + GSK3640254 200 mg
Day 40.55 ± 0.225
Day 70.55 ± 0.329
Day 100.52 ± 0.315
SecondaryPeriod 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Millimoles per liter
Period 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Millimoles per literDolutegravir 50 mg
Glucose0.063 ± 0.4235
Cholesterol0.088 ± 0.6858
Triglycerides-0.084 ± 0.3983
Anion gap-1.2 ± 1.33
Calcium0.025 ± 0.0599
Carbon dioxide-0.1 ± 2.03
Chloride1.6 ± 2.63
Phosphate0.091 ± 0.1531
Potassium0.05 ± 0.356
Sodium0.3 ± 2.15
Blood urea nitrogen0.297 ± 0.9823
SecondaryPeriod 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Millimoles per liter
Period 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Millimoles per literGSK3640254 200 mg
Glucose-0.249 ± 0.1748
Cholesterol-0.269 ± 0.2363
Triglycerides0.087 ± 0.2374
Anion gap2.2 ± 1.52
Calcium0.014 ± 0.0245
Carbon dioxide-1.3 ± 1.53
Chloride-0.7 ± 1.78
Phosphate0.037 ± 0.0955
Potassium-0.03 ± 0.272
Sodium0.3 ± 1.74
Blood urea nitrogen-0.341 ± 0.3937
SecondaryPeriod 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Millimoles per liter
Period 3: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Millimoles per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Glucose0.062 ± 0.1638
Day 7: Glucose0.103 ± 0.1806
Day 10: Glucose-0.066 ± 0.2205
Day 4: Cholesterol0.096 ± 0.2400
Day 7: Cholesterol-0.008 ± 0.2693
Day 10: Cholesterol-0.030 ± 0.2366
Day 4: Triglycerides0.034 ± 0.2316
Day 7: Triglycerides-0.094 ± 0.2578
Day 10: Triglycerides0.095 ± 0.2178
Day 4: Anion gap-4.1 ± 1.24
Day 7: Anion gap0.1 ± 1.69
Day 10: Anion gap0.8 ± 1.65
Day 4: Calcium-0.003 ± 0.0416
Day 7: Calcium0.026 ± 0.0413
Day 10: Calcium:0.035 ± 0.0561
Day 4: Carbon dioxide0.9 ± 1.65
Day 7: Carbon dioxide0.1 ± 1.59
Day 10: Carbon dioxide1.0 ± 2.16
Day 4: Chloride0.7 ± 1.92
Day 7: Chloride-0.3 ± 1.39
Day 10: Chloride-1.1 ± 1.86
Day 4: Phosphate-0.004 ± 0.0808
Day 7: Phosphate-0.013 ± 0.1151
Day 10: Phosphate-0.051 ± 0.1115
Day 4: Potassium-0.04 ± 0.239
Day 7: Potassium-0.03 ± 0.218
Day 10: Potassium0.06 ± 0.189
Day 4: Sodium-2.0 ± 1.37
Day 7: Sodium-0.1 ± 1.65
Day 10: Sodium0.5 ± 1.90
Day 4: Blood urea nitrogen0.054 ± 0.5287
Day 7: Blood urea nitrogen-0.178 ± 0.3542
Day 10: Blood urea nitrogen-0.026 ± 0.5156
SecondaryPeriod 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · International units per liter
Period 1: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase
International units per literDolutegravir 50 mg
Creatine kinase-32.0 ± 61.33
Lactate dehydrogenase-21.9 ± 14.16
ALT-0.3 ± 8.28
ALP-0.1 ± 7.67
AST-0.7 ± 3.36
Gamma-glutamyl transferase-2.1 ± 3.13
SecondaryPeriod 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · International units per liter
Period 2: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literGSK3640254 200 mg
Creatine kinase22.6 ± 58.21
Lactate dehydrogenase9.1 ± 5.76
ALT-0.6 ± 2.80
ALP1.9 ± 2.70
AST0.2 ± 1.87
Gamma-glutamyl transferase-0.8 ± 1.28
SecondaryPeriod 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · International units per liter
Period 3: Change From Baseline in Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Creatine kinase-32.1 ± 131.30
Day 7: Creatine kinase-37.1 ± 158.35
Day 10: Creatine kinase-42.1 ± 162.94
Day 4: Lactate dehydrogenase5.9 ± 7.38
Day 7: Lactate dehydrogenase-0.9 ± 7.02
Day 10: Lactate dehydrogenase0.1 ± 10.32
Day 4: ALT1.1 ± 4.36
Day 7: ALT0.7 ± 4.69
Day 10: ALT1.9 ± 4.11
Day 4: ALP-1.6 ± 2.00
Day 7: ALP-0.6 ± 2.39
Day 10: ALP0.8 ± 4.06
Day 4: AST0.9 ± 2.45
Day 7: AST-0.5 ± 2.68
Day 10: AST0.3 ± 2.29
Day 4: Gamma-glutamyl transferase-0.8 ± 0.75
Day 7: Gamma-glutamyl transferase-0.3 ± 1.06
Day 10: Gamma-glutamyl transferase0.5 ± 1.51
SecondaryPeriod 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Micromoles per liter
Period 1: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literDolutegravir 50 mg
Urate-32.3 ± 42.01
Creatinine5.41 ± 7.253
Bilirubin0.01 ± 4.516
Direct bilirubin0.03 ± 0.677
SecondaryPeriod 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Micromoles per liter
Period 2: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literGSK3640254 200 mg
Urate-7.1 ± 14.52
Creatinine-3.36 ± 4.219
Bilirubin0.27 ± 1.299
Direct bilirubin0.06 ± 0.328
SecondaryPeriod 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Micromoles per liter
Period 3: Change From Baseline in Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Urate0.0 ± 16.23
Day 7: Urate-15.6 ± 26.39
Day 10: Urate-1.4 ± 24.69
Day 4: Creatinine7.90 ± 4.239
Day 7: Creatinine9.89 ± 4.014
Day 10: Creatinine1.99 ± 4.739
Day 4: Bilirubin2.24 ± 2.659
Day 7: Bilirubin-0.21 ± 1.455
Day 10: Bilirubin1.43 ± 2.011
Day 4: Direct bilirubin0.33 ± 0.425
Day 7: Direct bilirubin-0.19 ± 0.436
Day 10: Direct bilirubin0.22 ± 0.248
SecondaryPeriod 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Grams per liter
Period 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein
Grams per literDolutegravir 50 mg
Albumin0.4 ± 2.45
Globulin0.8 ± 1.11
Protein1.2 ± 3.06
SecondaryPeriod 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Grams per liter
Period 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein
Grams per literGSK3640254 200 mg
Albumin0.9 ± 1.45
Globulin-1.1 ± 0.77
Protein-0.2 ± 1.76
SecondaryPeriod 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Grams per liter
Period 3: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Protein
Grams per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Albumin0.9 ± 1.00
Day 7: Albumin0.2 ± 1.22
Day 10: Albumin0.4 ± 2.06
Day 4: Globulin-0.9 ± 1.29
Day 7: Globulin1.0 ± 1.10
Day 10: Globulin0.5 ± 1.32
Day 4: Protein0.0 ± 1.75
Day 7: Protein1.2 ± 1.80
Day 10: Protein0.9 ± 2.90
SecondaryPeriod 1: Change From Baseline in Chemistry Parameters: Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Units per liter
Period 1: Change From Baseline in Chemistry Parameters: Amylase, Lipase
Units per literDolutegravir 50 mg
Amylase3.1 ± 9.63
Lipase-3.4 ± 8.97
SecondaryPeriod 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Units per liter
Period 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase
Units per literGSK3640254 200 mg
Amylase-2.8 ± 4.65
Lipase-0.7 ± 3.79
SecondaryPeriod 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Units per liter
Period 3: Change From Baseline in Chemistry Parameters: Amylase, Lipase
Units per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Amylase-1.6 ± 3.18
Day 7: Amylase0.1 ± 4.25
Day 10: Amylase-0.9 ± 6.08
Day 4: Lipase4.7 ± 6.10
Day 7: Lipase-0.8 ± 4.76
Day 10: Lipase0.1 ± 5.24
SecondaryPeriod 1: Change From Baseline in Urinalysis Parameter: Specific Gravity

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Ratio
Period 1: Change From Baseline in Urinalysis Parameter: Specific Gravity
RatioDolutegravir 50 mg
Period 1: Change From Baseline in Urinalysis Parameter: Specific Gravity0.0053 ± 0.00865
SecondaryPeriod 2: Change From Baseline in Urinalysis Parameter: Specific Gravity

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Ratio
Period 2: Change From Baseline in Urinalysis Parameter: Specific Gravity
RatioGSK3640254 200 mg
Period 2: Change From Baseline in Urinalysis Parameter: Specific Gravity-0.0004 ± 0.00645
SecondaryPeriod 3: Change From Baseline in Urinalysis Parameter: Specific Gravity

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Ratio
Period 3: Change From Baseline in Urinalysis Parameter: Specific Gravity
RatioDolutegravir 50 mg + GSK3640254 200 mg
Day 40.0003 ± 0.00652
Day 7-0.0007 ± 0.00545
Day 10-0.0016 ± 0.00901
SecondaryPeriod 1: Change From Baseline in Urinalysis Parameter: Urobilinogen

Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · Micromoles per liter
Period 1: Change From Baseline in Urinalysis Parameter: Urobilinogen
Micromoles per literDolutegravir 50 mg
Period 1: Change From Baseline in Urinalysis Parameter: Urobilinogen0.0000 ± 0.00000
SecondaryPeriod 2: Change From Baseline in Urinalysis Parameter: Urobilinogen

Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · Micromoles per liter
Period 2: Change From Baseline in Urinalysis Parameter: Urobilinogen
Micromoles per literGSK3640254 200 mg
Period 2: Change From Baseline in Urinalysis Parameter: Urobilinogen0.0000 ± 0.00000
SecondaryPeriod 3: Change From Baseline in Urinalysis Parameter: Urobilinogen

Urine samples were collected to analyze the urinalysis parameter: urobilinogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · Micromoles per liter
Period 3: Change From Baseline in Urinalysis Parameter: Urobilinogen
Micromoles per literDolutegravir 50 mg + GSK3640254 200 mg
Day 40.0000 ± 0.00000
Day 70.0000 ± 0.00000
Day 100.0000 ± 0.00000
SecondaryPeriod 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH)

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day -1) and at Day 9
Reported as:
Mean · pH
Period 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH)
pHDolutegravir 50 mg
Period 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH)-0.22 ± 0.730
SecondaryPeriod 2: Change From Baseline in Urinalysis Parameter: pH

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 1 Day 9) and at Day 7
Reported as:
Mean · pH
Period 2: Change From Baseline in Urinalysis Parameter: pH
pHGSK3640254 200 mg
Period 2: Change From Baseline in Urinalysis Parameter: pH0.13 ± 0.428
SecondaryPeriod 3: Change From Baseline in Urinalysis Parameter: pH

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, before the first treatment in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Period 2 Day 7) and at Days 4, 7 and 10
Reported as:
Mean · pH
Period 3: Change From Baseline in Urinalysis Parameter: pH
pHDolutegravir 50 mg + GSK3640254 200 mg
Day 40.03 ± 0.531
Day 7-0.13 ± 0.500
Day 100.16 ± 0.569
SecondaryPeriod 1: Number of Participants With Urinalysis Dipstick Results

Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present) and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.

Time frame:
Day 9
Reported as:
Count of participants · Participants
Period 1: Number of Participants With Urinalysis Dipstick Results
ParticipantsDolutegravir 50 mg
Bilirubin: Negative16
Glucose: Negative16
Ketones: Negative15
Ketones: Trace1
Leukocyte Esterase: Negative16
Nitrite: Negative16
Occult Blood: Negative15
Occult Blood: 2+1
Protein: Negative16
SecondaryPeriod 2: Number of Participants With Urinalysis Dipstick Results

Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present) indicating proportional concentrations in the urine sample.

Time frame:
Day 7
Reported as:
Count of participants · Participants
Period 2: Number of Participants With Urinalysis Dipstick Results
ParticipantsGSK3640254 200 mg
Bilirubin: Negative16
Glucose: Negative16
Ketones: Negative15
Ketones: 1+1
Leukocyte Esterase: Negative15
Leukocyte Esterase: 1+1
Nitrite: Negative16
Occult Blood: Negative16
Protein: Negative16
SecondaryPeriod 3: Number of Participants With Urinalysis Dipstick Results

Urine samples were collected at indicated time points to analyze parameters including glucose, protein, occult blood, ketones, nitrite, bilirubin and leukocyte esterase levels by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace, 1+ (low concentrations present), and 2+ (moderate concentrations present)indicating proportional concentrations in the urine sample.

Time frame:
Days 4, 7 and 10
Reported as:
Count of participants · Participants
Period 3: Number of Participants With Urinalysis Dipstick Results
ParticipantsDolutegravir 50 mg + GSK3640254 200 mg
Bilirubin: Day 4, Negative16
Bilirubin: Day 7, Negative16
Bilirubin: Day 10, Negative16
Glucose: Day 4, Negative16
Glucose: Day 7, Negative16
Glucose: Day 10, Negative16
Ketones: Day 4, Negative16
Ketones: Day 7, Negative16
Ketones: Day 10, Negative16
Leukocyte Esterase: Day 4, Negative16
Leukocyte Esterase: Day 7, Negative16
Leukocyte Esterase: Day 10, Negative16
Nitrite: Day 4, Negative16
Nitrite: Day 7, Negative16
Nitrite: Day 10, Negative16
Occult Blood: Day 4, Negative16
Occult Blood: Day 7, Negative16
Occult Blood: Day 10, Negative16
Protein: Day 4, Negative16
Protein: Day 7, Negative16
Protein: Day 10, Negative16
SecondaryPeriod 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB)

Twelve-lead electrocardiograms (ECG) were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline, Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Reported as:
Mean · Milliseconds
Period 1: Change From Baseline in PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF), Bazett's QT Correction Formula (QTcB)
MillisecondsDolutegravir 50 mg
PR Interval: Day 1, 2 hours-0.5 ± 9.33
PR Interval: Day 1, 4 hours1.7 ± 8.34
PR Interval: Day 5, Pre-dose4.7 ± 6.32
PR Interval: Day 5, 2 hours1.3 ± 8.52
PR Interval: Day 5, 4 hours1.9 ± 12.94
QRS Duration: Day 1, 2 hours1.8 ± 3.04
QRS Duration: Day 1, 4 hours1.3 ± 3.32
QRS Duration: Day 5, Pre-dose-0.8 ± 3.21
QRS Duration: Day 5, 2 hours0.8 ± 3.99
QRS Duration: Day 5, 4 hours0.6 ± 2.78
QT Interval: Day 1, 2 hours-5.5 ± 8.21
QT Interval: Day 1, 4 hours9.9 ± 12.91
QT Interval: Day 5, Pre-dose-6.8 ± 11.74
QT Interval: Day 5, 2 hours-16.3 ± 16.64
QT Interval: Day 5, 4 hours1.2 ± 16.07
QTcF Interval: Day 1, 2 hours-5.0 ± 8.42
QTcF Interval: Day 1, 4 hours-1.6 ± 8.52
QTcF Interval: Day 5, Pre-dose-7.1 ± 8.53
QTcF Interval: Day 5, 2 hours-7.9 ± 9.92
QTcF Interval: Day 5, 4 hours-3.9 ± 7.56
QTcB Interval: Day 1, 2 hours-4.5 ± 10.26
QTcB Interval: Day 1, 4 hours-7.4 ± 9.16
QTcB Interval: Day 5, Pre-dose-6.7 ± 8.16
QTcB Interval: Day 5, 2 hours-3.4 ± 10.84
QTcB Interval: Day 5, 4 hours-5.9 ± 11.62
SecondaryPeriod 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments on Day 1 of Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline; Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Reported as:
Mean · Milliseconds
Period 2: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB
MillisecondsGSK3640254 200 mg
PR Interval: Day 1, 2 hours-3.3 ± 6.31
PR Interval: Day 1, 4 hours-3.0 ± 5.55
PR Interval: Day 5, Pre-dose-2.1 ± 6.15
PR Interval: Day 5, 2 hours-3.4 ± 7.81
PR Interval: Day 5, 4 hours-6.4 ± 6.77
QRS Duration: Day 1, 2 hours0.1 ± 2.54
QRS Duration: Day 1, 4 hours-1.1 ± 4.08
QRS Duration: Day 5, Pre-dose0.3 ± 3.89
QRS Duration: Day 5, 2 hours-0.2 ± 3.85
QRS Duration: Day 5, 4 hours0.6 ± 2.70
QT Interval: Day 1, 2 hours-7.9 ± 11.47
QT Interval: Day 1, 4 hours4.6 ± 13.48
QT Interval: Day 5, Pre-dose2.8 ± 17.38
QT Interval: Day 5, 2 hours-7.1 ± 16.13
QT Interval: Day 5, 4 hours6.3 ± 20.51
QTcF Interval: Day 1, 2 hours-1.3 ± 8.74
QTcF Interval: Day 1, 4 hours3.1 ± 6.44
QTcF Interval: Day 5, Pre-dose6.6 ± 6.79
QTcF Interval: Day 5, 2 hours3.7 ± 9.36
QTcF Interval: Day 5, 4 hours10.2 ± 10.44
QTcB Interval: Day 1, 2 hours2.4 ± 13.45
QTcB Interval: Day 1, 4 hours2.6 ± 12.62
QTcB Interval: Day 5, Pre-dose8.4 ± 5.92
QTcB Interval: Day 5, 2 hours9.9 ± 11.93
QTcB Interval: Day 5, 4 hours12.4 ± 8.57
SecondaryPeriod 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline; Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10
Reported as:
Mean · Milliseconds
Period 3: Change From Baseline in PR Interval, QRS Duration, QT Interval, QTcF, QTcB
MillisecondsDolutegravir 50 mg + GSK3640254 200 mg
PR Interval: Day 1, 2 hours1.9 ± 7.47
PR Interval: Day 1, 4 hours-1.9 ± 8.19
PR Interval: Day 4, Pre-dose-0.4 ± 6.97
PR Interval: Day 4, 2 hours0.9 ± 8.48
PR Interval: Day 4, 4 hours-2.9 ± 9.53
PR Interval: Day 5, Pre-dose-1.4 ± 10.59
PR Interval: Day 5, 2 hours-3.2 ± 9.13
PR Interval: Day 5, 4 hours-2.7 ± 7.77
PR Interval: Day 7, Pre-dose3.6 ± 7.61
PR Interval: Day 7, 2 hours-1.0 ± 9.47
PR Interval: Day 7, 4 hours-0.4 ± 7.61
PR Interval: Day 102.3 ± 8.60
QRS Duration: Day 1, 2 hours1.1 ± 5.47
QRS Duration: Day 1, 4 hours-2.1 ± 3.80
QRS Duration: Day 4, Pre-dose2.0 ± 5.61
QRS Duration: Day 4, 2 hours-1.3 ± 3.09
QRS Duration: Day 4, 4 hours0.5 ± 6.63
QRS Duration: Day 5, Pre-dose1.8 ± 6.18
QRS Duration: Day 5, 2 hours1.3 ± 5.11
QRS Duration: Day 5, 4 hours-0.5 ± 3.31
QRS Duration: Day 7, Pre-dose0.6 ± 3.58
QRS Duration: Day 7, 2 hours0.3 ± 4.93
QRS Duration: Day 7, 4 hours-0.4 ± 3.72
QRS Duration: Day 101.7 ± 5.45
QT Interval: Day 1, 2 hours-7.8 ± 8.68
QT Interval: Day 1, 4 hours4.4 ± 13.15
QT Interval: Day 4, Pre-dose1.4 ± 14.28
QT Interval: Day 4, 2 hours-11.2 ± 14.53
QT Interval: Day 4, 4 hours7.4 ± 13.68
QT Interval: Day 5, Pre-dose-1.4 ± 13.57
QT Interval: Day 5, 2 hours-6.9 ± 10.65
QT Interval: Day 5, 4 hours3.9 ± 14.59
QT Interval: Day 7, Pre-dose3.2 ± 17.34
QT Interval: Day 7, 2 hours-5.6 ± 14.01
QT Interval: Day 7, 4 hours8.0 ± 15.38
QT Interval: Day 105.1 ± 10.39
QTcF Interval: Day 1, 2 hours-0.4 ± 5.63
QTcF Interval: Day 1, 4 hours6.6 ± 4.97
QTcF Interval: Day 4, Pre-dose2.7 ± 8.21
QTcF Interval: Day 4, 2 hours-2.5 ± 8.41
QTcF Interval: Day 4, 4 hours8.1 ± 9.10
QTcF Interval: Day 5, Pre-dose6.1 ± 8.14
QTcF Interval: Day 5, 2 hours1.1 ± 9.42
QTcF Interval: Day 5, 4 hours8.6 ± 6.26
QTcF Interval: Day 7, Pre-dose2.0 ± 9.21
QTcF Interval: Day 7, 2 hours0.6 ± 7.46
QTcF Interval: Day 7, 4 hours3.6 ± 7.28
QTcF Interval: Day 101.6 ± 7.36
QTcB Interval: Day 1, 2 hours3.8 ± 9.50
QTcB Interval: Day 1, 4 hours7.4 ± 10.78
QTcB Interval: Day 4, Pre-dose3.8 ± 13.72
QTcB Interval: Day 4, 2 hours-0.6 ± 17.78
QTcB Interval: Day 4, 4 hours8.6 ± 12.83
QTcB Interval: Day 5, Pre-dose10.6 ± 13.25
QTcB Interval: Day 5, 2 hours5.5 ± 12.47
QTcB Interval: Day 5, 4 hours11.3 ± 9.50
QTcB Interval: Day 7, Pre-dose2.1 ± 14.09
QTcB Interval: Day 7, 2 hours4.4 ± 14.43
QTcB Interval: Day 7, 4 hours1.4 ± 10.35
QTcB Interval: Day 100.2 ± 10.89
SecondaryPeriod 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Reported as:
Mean · Millimeters of mercury
Period 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryDolutegravir 50 mg
SBP: Day 23.5 ± 9.97
SBP: Day 3-0.4 ± 8.88
SBP: Day 43.7 ± 11.97
SBP: Day 5-6.2 ± 8.88
DBP: Day 24.3 ± 6.70
DBP: Day 30.9 ± 9.89
DBP: Day 42.3 ± 8.50
DBP: Day 5-2.6 ± 10.70
SecondaryPeriod 2: Change From Baseline in SBP and DBP

SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Millimeters of mercury
Period 2: Change From Baseline in SBP and DBP
Millimeters of mercuryGSK3640254 200 mg
SBP: Day 21.7 ± 5.19
SBP: Day 31.3 ± 6.83
SBP: Day 43.0 ± 7.73
SBP: Day 5-0.5 ± 5.40
SBP: Day 6-0.1 ± 8.01
SBP: Day 70.6 ± 4.57
DBP: Day 2-0.4 ± 7.03
DBP: Day 31.1 ± 4.46
DBP: Day 4-0.4 ± 4.67
DBP: Day 5-1.3 ± 4.85
DBP: Day 60.3 ± 6.37
DBP: Day 70.4 ± 5.62
SecondaryPeriod 3: Change From Baseline in SBP and DBP

SBP and DBP were measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Millimeters of mercury
Period 3: Change From Baseline in SBP and DBP
Millimeters of mercuryDolutegravir 50 mg + GSK3640254 200 mg
SBP: Day 2-0.1 ± 7.66
SBP: Day 3-3.4 ± 6.54
SBP: Day 4-3.3 ± 6.63
SBP: Day 53.6 ± 17.17
SBP: Day 6-1.4 ± 7.08
SBP: Day 7-2.1 ± 7.76
SBP: Day 8-2.0 ± 9.36
SBP: Day 9-2.3 ± 8.00
SBP: Day 10-4.3 ± 8.35
SBP: Day 11-3.4 ± 7.69
DBP: Day 21.3 ± 3.32
DBP: Day 3-0.1 ± 5.73
DBP: Day 41.2 ± 4.51
DBP: Day 56.7 ± 22.20
DBP: Day 61.4 ± 6.99
DBP: Day 72.9 ± 5.88
DBP: Day 81.8 ± 9.89
DBP: Day 92.1 ± 5.87
DBP: Day 102.3 ± 4.91
DBP: Day 11-0.1 ± 5.43
SecondaryPeriod 1: Change From Baseline in Pulse Rate

Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Reported as:
Mean · Beats per minute
Period 1: Change From Baseline in Pulse Rate
Beats per minuteDolutegravir 50 mg
Day 2-0.3 ± 4.30
Day 3-1.3 ± 4.63
Day 42.0 ± 8.46
Day 5-1.6 ± 5.08
SecondaryPeriod 2: Change From Baseline in Pulse Rate

Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Beats per minute
Period 2: Change From Baseline in Pulse Rate
Beats per minuteGSK3640254 200 mg
Day 23.9 ± 8.54
Day 35.4 ± 7.19
Day 44.8 ± 7.50
Day 54.2 ± 8.73
Day 63.8 ± 6.51
Day 72.7 ± 5.78
SecondaryPeriod 3: Change From Baseline in Pulse Rate

Pulse rate was measured in the semi-recumbent position with a completely automated device. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Beats per minute
Period 3: Change From Baseline in Pulse Rate
Beats per minuteDolutegravir 50 mg + GSK3640254 200 mg
Day 21.8 ± 5.65
Day 32.2 ± 6.88
Day 40.3 ± 7.63
Day 53.1 ± 7.79
Day 61.3 ± 6.97
Day 7-2.1 ± 5.94
Day 82.3 ± 9.34
Day 9-0.8 ± 7.90
Day 10-2.9 ± 5.34
Day 111.7 ± 10.56
SecondaryPeriod 1: Change From Baseline in Respiratory Rate

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Reported as:
Mean · Breaths per minute
Period 1: Change From Baseline in Respiratory Rate
Breaths per minuteDolutegravir 50 mg
Day 2-0.9 ± 3.18
Day 30.3 ± 2.05
Day 4-1.5 ± 3.06
Day 5-0.8 ± 2.29
SecondaryPeriod 2: Change From Baseline in Respiratory Rate

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Breaths per minute
Period 2: Change From Baseline in Respiratory Rate
Breaths per minuteGSK3640254 200 mg
Day 2, n=16-0.5 ± 2.58
Day 3, n=160.4 ± 3.03
Day 4, n=16-0.6 ± 3.07
Day 5, n=151.3 ± 2.47
Day 6, n=16-0.4 ± 2.55
Day 7, n=160.1 ± 3.30
SecondaryPeriod 3: Change From Baseline in Respiratory Rate

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Breaths per minute
Period 3: Change From Baseline in Respiratory Rate
Breaths per minuteDolutegravir 50 mg + GSK3640254 200 mg
Day 21.4 ± 3.07
Day 30.5 ± 3.39
Day 40.3 ± 3.34
Day 5-0.5 ± 2.97
Day 60.6 ± 3.24
Day 70.3 ± 3.09
Day 81.4 ± 2.80
Day 9-0.4 ± 3.36
Day 101.4 ± 2.80
Day 112.8 ± 2.41
SecondaryPeriod 1: Change From Baseline in Body Temperature

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4 and 5
Reported as:
Mean · Degrees Celsius
Period 1: Change From Baseline in Body Temperature
Degrees CelsiusDolutegravir 50 mg
Day 2-0.04 ± 0.326
Day 3-0.14 ± 0.287
Day 4-0.19 ± 0.370
Day 50.03 ± 0.275
SecondaryPeriod 2: Change From Baseline in Body Temperature

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 2. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Degrees Celsius
Period 2: Change From Baseline in Body Temperature
Degrees CelsiusGSK3640254 200 mg
Day 2-0.14 ± 0.299
Day 3-0.25 ± 0.415
Day 4-0.19 ± 0.294
Day 5-0.05 ± 0.363
Day 6-0.13 ± 0.300
Day 7-0.13 ± 0.373
SecondaryPeriod 3: Change From Baseline in Body Temperature

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, in Period 3. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Degrees Celsius
Period 3: Change From Baseline in Body Temperature
Degrees CelsiusDolutegravir 50 mg + GSK3640254 200 mg
Day 2-0.08 ± 0.286
Day 3-0.18 ± 0.423
Day 40.02 ± 0.229
Day 50.00 ± 0.175
Day 6-0.03 ± 0.318
Day 70.06 ± 0.287
Day 8-0.13 ± 0.458
Day 9-0.10 ± 0.329
Day 10-0.03 ± 0.291
Day 110.13 ± 0.302
SecondaryPeriod 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

Time frame:
Day 9
Reported as:
Mean · 10^9 cells per liter
Period 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
10^9 cells per literDolutegravir 50 mg
Basophils0.045 ± 0.0115
Eosinophils0.232 ± 0.1440
Lymphocytes2.023 ± 0.5931
Monocytes0.512 ± 0.1133
Neutrophils3.038 ± 0.7559
Platelet count270.2 ± 47.62
SecondaryPeriod 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

Time frame:
Day 7
Reported as:
Mean · 10^9 cells per liter
Period 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
10^9 cells per literGSK3640254 200 mg
Basophils0.039 ± 0.0134
Eosinophils0.206 ± 0.0960
Lymphocytes1.869 ± 0.4383
Monocytes0.488 ± 0.1081
Neutrophils2.878 ± 0.6859
Platelet count264.2 ± 48.37
SecondaryPeriod 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · 10^9 cells per liter
Period 3: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count
10^9 cells per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Basophils, n=160.043 ± 0.0165
Day 7: Basophils, n=160.046 ± 0.0196
Day 10: Basophils, n=160.042 ± 0.0142
Day 4: Eosinophils, n=160.206 ± 0.1120
Day 7: Eosinophils, n=160.211 ± 0.1512
Day 10: Eosinophils, n=160.171 ± 0.0874
Day 4: Lymphocytes, n=161.739 ± 0.3701
Day 7: Lymphocytes, n=161.837 ± 0.3916
Day 10: Lymphocytes, n=161.753 ± 0.3450
Day 4: Monocytes, n=160.537 ± 0.1821
Day 7: Monocytes, n=160.490 ± 0.1157
Day 10: Monocytes, n=160.470 ± 0.1128
Day 4: Neutrophils, n=163.321 ± 1.4579
Day 7: Neutrophils, n=162.954 ± 0.5600
Day 10: Neutrophils, n=163.082 ± 0.6649
Day 4: Platelet count, n=16259.3 ± 46.03
Day 7: Platelet count, n=15255.3 ± 46.20
Day 10: Platelet count, n=16258.3 ± 42.92
SecondaryPeriod 1: Absolute Values for Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin.

Time frame:
Day 9
Reported as:
Mean · Grams per liter
Period 1: Absolute Values for Hematology Parameter: Hemoglobin
Grams per literDolutegravir 50 mg
Period 1: Absolute Values for Hematology Parameter: Hemoglobin146.4 ± 8.02
SecondaryPeriod 2: Absolute Values for Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin.

Time frame:
Day 7
Reported as:
Mean · Grams per liter
Period 2: Absolute Values for Hematology Parameter: Hemoglobin
Grams per literGSK3640254 200 mg
Period 2: Absolute Values for Hematology Parameter: Hemoglobin146.5 ± 8.68
SecondaryPeriod 3: Absolute Values for Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Grams per liter
Period 3: Absolute Values for Hematology Parameter: Hemoglobin
Grams per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4149.8 ± 8.74
Day 7147.1 ± 8.23
Day 10147.7 ± 9.17
SecondaryPeriod 1: Absolute Values for Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit.

Time frame:
Day 9
Reported as:
Mean · Proportion of red blood cells in blood
Period 1: Absolute Values for Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodDolutegravir 50 mg
Period 1: Absolute Values for Hematology Parameter: Hematocrit0.4419 ± 0.01697
SecondaryPeriod 2: Absolute Values for Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit.

Time frame:
Day 7
Reported as:
Mean · Proportion of red blood cells in blood
Period 2: Absolute Values for Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodGSK3640254 200 mg
Period 2: Absolute Values for Hematology Parameter: Hematocrit0.4406 ± 0.01887
SecondaryPeriod 3: Absolute Values for Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Proportion of red blood cells in blood
Period 3: Absolute Values for Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodDolutegravir 50 mg + GSK3640254 200 mg
Day 40.4441 ± 0.01956
Day 70.4357 ± 0.01924
Day 100.4364 ± 0.02267
SecondaryPeriod 1: Absolute Values for Hematology Parameter: Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes.

Time frame:
Day 9
Reported as:
Mean · Trillion cells per liter
Period 1: Absolute Values for Hematology Parameter: Erythrocytes
Trillion cells per literDolutegravir 50 mg
Period 1: Absolute Values for Hematology Parameter: Erythrocytes5.143 ± 0.3580
SecondaryPeriod 2: Absolute Values for Hematology Parameter: Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes.

Time frame:
Day 7
Reported as:
Mean · Trillion cells per liter
Period 2: Absolute Values for Hematology Parameter: Erythrocytes
Trillion cells per literGSK3640254 200 mg
Period 2: Absolute Values for Hematology Parameter: Erythrocytes5.179 ± 0.3575
SecondaryPeriod 3: Absolute Values for Hematology Parameter: Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Trillion cells per liter
Period 3: Absolute Values for Hematology Parameter: Erythrocytes
Trillion cells per literDolutegravir 50 mg + GSK3640254 200 mg
Day 45.194 ± 0.3476
Day 75.099 ± 0.3798
Day 105.124 ± 0.3678
SecondaryPeriod 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

Time frame:
Day 9
Reported as:
Mean · Femtoliter
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
FemtoliterDolutegravir 50 mg
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume86.22 ± 5.670
SecondaryPeriod 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

Time frame:
Day 7
Reported as:
Mean · Femtoliter
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
FemtoliterGSK3640254 200 mg
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume85.36 ± 5.509
SecondaryPeriod 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Femtoliter
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
FemtoliterDolutegravir 50 mg + GSK3640254 200 mg
Day 485.76 ± 5.323
Day 785.72 ± 5.117
Day 1085.41 ± 5.030
SecondaryPeriod 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

Time frame:
Day 9
Reported as:
Mean · Picograms
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
PicogramsDolutegravir 50 mg
Period 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin28.58 ± 2.446
SecondaryPeriod 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

Time frame:
Day 7
Reported as:
Mean · Picograms
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
PicogramsGSK3640254 200 mg
Period 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin28.41 ± 2.385
SecondaryPeriod 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Picograms
Period 3: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
PicogramsDolutegravir 50 mg + GSK3640254 200 mg
Day 428.96 ± 2.514
Day 728.96 ± 2.404
Day 1028.93 ± 2.530
SecondaryPeriod 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

Time frame:
Day 9
Reported as:
Mean · Millimoles per liter
Period 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Millimoles per literDolutegravir 50 mg
Glucose5.165 ± 0.4788
Cholesterol4.456 ± 0.6591
Triglycerides1.107 ± 0.5362
Anion gap9.2 ± 1.28
Calcium2.393 ± 0.0781
Carbon dioxide30.5 ± 1.15
Chloride103.8 ± 2.32
Phosphate1.244 ± 0.1658
Potassium4.31 ± 0.427
Sodium139.3 ± 2.52
Blood urea nitrogen5.406 ± 0.7575
SecondaryPeriod 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

Time frame:
Day 7
Reported as:
Mean · Millimoles per liter
Period 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Millimoles per literGSK3640254 200 mg
Glucose4.916 ± 0.4825
Cholesterol4.187 ± 0.6783
Triglycerides1.194 ± 0.7294
Anion gap11.4 ± 1.20
Calcium2.406 ± 0.0772
Carbon dioxide29.3 ± 1.57
Chloride103.1 ± 2.35
Phosphate1.281 ± 0.1510
Potassium4.23 ± 0.249
Sodium139.6 ± 1.90
Blood urea nitrogen5.065 ± 0.6775
SecondaryPeriod 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected to analyze the chemistry parameters: glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and blood urea nitrogen.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Millimoles per liter
Period 3: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
Millimoles per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Glucose4.978 ± 0.4655
Day 7: Glucose5.018 ± 0.3977
Day 10: Glucose4.849 ± 0.3858
Day 4: Cholesterol4.283 ± 0.8001
Day 7: Cholesterol4.179 ± 0.7438
Day 10: Cholesterol4.157 ± 0.8037
Day 4: Triglycerides1.228 ± 0.6403
Day 7: Triglycerides1.100 ± 0.5887
Day 10: Triglycerides1.289 ± 0.6625
Day 4: Anion gap7.3 ± 1.01
Day 7: Anion gap11.4 ± 1.75
Day 10: Anion gap12.1 ± 1.31
Day 4: Calcium2.404 ± 0.0855
Day 7: Calcium2.433 ± 0.0827
Day 10: Calcium2.441 ± 0.0681
Day 4: Carbon dioxide30.2 ± 1.56
Day 7: Carbon dioxide29.4 ± 1.15
Day 10: Carbon dioxide30.3 ± 1.53
Day 4: Chloride103.8 ± 2.77
Day 7: Chloride102.8 ± 2.07
Day 10: Chloride101.9 ± 2.02
Day 4: Phosphate1.276 ± 0.1304
Day 7: Phosphate1.268 ± 0.1802
Day 10: Phosphate1.229 ± 0.1213
Day 4: Potassium4.19 ± 0.150
Day 7: Potassium4.19 ± 0.217
Day 10: Potassium4.29 ± 0.275
Day 4: Sodium137.6 ± 2.06
Day 7: Sodium139.5 ± 2.56
Day 10: Sodium140.1 ± 2.11
Day 4: Blood urea nitrogen5.119 ± 0.8548
Day 7: Blood urea nitrogen4.887 ± 0.6388
Day 10: Blood urea nitrogen5.039 ± 0.8264
SecondaryPeriod 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

Time frame:
Day 9
Reported as:
Mean · International units per liter
Period 1: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literDolutegravir 50 mg
Creatine kinase101.3 ± 57.10
Lactate dehydrogenase107.4 ± 14.33
ALT21.0 ± 10.71
ALP57.4 ± 8.74
AST16.6 ± 3.86
Gamma-glutamyl transferase21.1 ± 9.24
SecondaryPeriod 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

Time frame:
Day 7
Reported as:
Mean · International units per liter
Period 2: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literGSK3640254 200 mg
Creatine kinase123.9 ± 112.28
Lactate dehydrogenase116.5 ± 15.10
ALT20.4 ± 9.88
ALP59.3 ± 9.19
AST16.8 ± 3.80
Gamma-glutamyl transferase20.3 ± 8.44
SecondaryPeriod 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · International units per liter
Period 3: Absolute Values for Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Creatine kinase110.3 ± 67.02
Day 7: Creatine kinase105.3 ± 63.83
Day 10: Creatine kinase100.3 ± 50.51
Day 4: Lactate dehydrogenase122.4 ± 16.26
Day 7: Lactate dehydrogenase115.6 ± 15.47
Day 10: Lactate dehydrogenase116.6 ± 18.79
Day 4: ALT21.4 ± 11.98
Day 7: ALT21.1 ± 12.00
Day 10: ALT22.3 ± 12.93
Day 4: ALP57.8 ± 9.34
Day 7: ALP58.8 ± 9.63
Day 10: ALP60.1 ± 9.07
Day 4: AST17.7 ± 5.12
Day 7: AST16.3 ± 4.78
Day 10: AST17.1 ± 4.55
Day 4: Gamma-glutamyl transferase19.5 ± 8.38
Day 7: Gamma-glutamyl transferase20.1 ± 8.35
Day 10: Gamma-glutamyl transferase20.8 ± 9.13
SecondaryPeriod 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

Time frame:
Day 9
Reported as:
Mean · Micromoles per liter
Period 1: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literDolutegravir 50 mg
Urate321.9 ± 64.43
Creatinine90.28 ± 11.281
Bilirubin9.14 ± 2.423
Direct bilirubin1.87 ± 0.551
SecondaryPeriod 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

Time frame:
Day 7
Reported as:
Mean · Micromoles per liter
Period 2: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literGSK3640254 200 mg
Urate314.8 ± 69.34
Creatinine86.92 ± 11.567
Bilirubin9.41 ± 3.014
Direct bilirubin1.93 ± 0.704
SecondaryPeriod 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Micromoles per liter
Period 3: Absolute Values for Chemistry Parameters: Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Urate314.8 ± 65.44
Day 7: Urate299.3 ± 62.85
Day 10: Urate313.4 ± 60.33
Day 4: Creatinine94.82 ± 13.650
Day 7: Creatinine96.81 ± 12.861
Day 10: Creatinine88.91 ± 12.545
Day 4: Bilirubin11.64 ± 4.856
Day 7: Bilirubin9.19 ± 2.511
Day 10: Bilirubin10.83 ± 3.796
Day 4: Direct bilirubin2.26 ± 0.995
Day 7: Direct bilirubin1.74 ± 0.617
Day 10: Direct bilirubin2.15 ± 0.784
SecondaryPeriod 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

Time frame:
Day 9
Reported as:
Mean · Grams per liter
Period 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein
Grams per literDolutegravir 50 mg
Albumin44.1 ± 3.32
Globulin27.9 ± 3.59
Protein71.9 ± 4.63
SecondaryPeriod 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

Time frame:
Day 7
Reported as:
Mean · Grams per liter
Period 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein
Grams per literGSK3640254 200 mg
Albumin44.9 ± 3.13
Globulin26.8 ± 3.78
Protein71.8 ± 4.73
SecondaryPeriod 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Grams per liter
Period 3: Absolute Values for Chemistry Parameters: Albumin, Globulin, Protein
Grams per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Albumin45.9 ± 3.12
Day 7: Albumin45.1 ± 2.83
Day 10: Albumin45.3 ± 2.80
Day 4: Globulin25.9 ± 3.52
Day 7: Globulin27.8 ± 3.49
Day 10: Globulin27.3 ± 3.34
Day 4: Protein71.8 ± 3.89
Day 7: Protein72.9 ± 4.28
Day 10: Protein72.6 ± 4.11
SecondaryPeriod 1: Absolute Values for Chemistry Parameters: Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

Time frame:
Day 9
Reported as:
Mean · Units per liter
Period 1: Absolute Values for Chemistry Parameters: Amylase, Lipase
Units per literDolutegravir 50 mg
Amylase59.6 ± 21.96
Lipase22.4 ± 8.57
SecondaryPeriod 2: Absolute Values for Chemistry Parameters: Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

Time frame:
Day 7
Reported as:
Mean · Units per liter
Period 2: Absolute Values for Chemistry Parameters: Amylase, Lipase
Units per literGSK3640254 200 mg
Amylase56.8 ± 19.06
Lipase21.7 ± 7.34
SecondaryPeriod 3: Absolute Values for Chemistry Parameters: Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Units per liter
Period 3: Absolute Values for Chemistry Parameters: Amylase, Lipase
Units per literDolutegravir 50 mg + GSK3640254 200 mg
Day 4: Amylase55.3 ± 18.81
Day 7: Amylase56.9 ± 21.03
Day 10: Amylase55.9 ± 20.57
Day 4: Lipase26.4 ± 11.10
Day 7: Lipase20.9 ± 9.12
Day 10: Lipase21.8 ± 9.25
SecondaryPeriod 1: Absolute Values for Urinalysis Parameter: Specific Gravity

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

Time frame:
Day 9
Reported as:
Mean · Ratio
Period 1: Absolute Values for Urinalysis Parameter: Specific Gravity
RatioDolutegravir 50 mg
Period 1: Absolute Values for Urinalysis Parameter: Specific Gravity1.0181 ± 0.00662
SecondaryPeriod 2: Absolute Values for Urinalysis Parameter: Specific Gravity

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

Time frame:
Day 7
Reported as:
Mean · Ratio
Period 2: Absolute Values for Urinalysis Parameter: Specific Gravity
RatioGSK3640254 200 mg
Period 2: Absolute Values for Urinalysis Parameter: Specific Gravity1.0176 ± 0.00552
SecondaryPeriod 3: Absolute Values for Urinalysis Parameter: Specific Gravity

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Ratio
Period 3: Absolute Values for Urinalysis Parameter: Specific Gravity
RatioDolutegravir 50 mg + GSK3640254 200 mg
Day 41.0179 ± 0.00712
Day 71.0169 ± 0.00640
Day 101.0160 ± 0.00747
SecondaryPeriod 1: Absolute Values for Urinalysis Parameter: Urobilinogen

Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

Time frame:
Day 9
Reported as:
Mean · Micromoles per liter
Period 1: Absolute Values for Urinalysis Parameter: Urobilinogen
Micromoles per literDolutegravir 50 mg
Period 1: Absolute Values for Urinalysis Parameter: Urobilinogen3.3860 ± 0.00000
SecondaryPeriod 2: Absolute Values for Urinalysis Parameter: Urobilinogen

Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

Time frame:
Day 7
Reported as:
Mean · Micromoles per liter
Period 2: Absolute Values for Urinalysis Parameter: Urobilinogen
Micromoles per literGSK3640254 200 mg
Period 2: Absolute Values for Urinalysis Parameter: Urobilinogen3.3860 ± 0.00000
SecondaryPeriod 3: Absolute Values for Urinalysis Parameter: Urobilinogen

Urine samples were collected to analyze the urinalysis parameter: urobilinogen.

Time frame:
Days 4, 7 and 10
Reported as:
Mean · Micromoles per liter
Period 3: Absolute Values for Urinalysis Parameter: Urobilinogen
Micromoles per literDolutegravir 50 mg + GSK3640254 200 mg
Day 43.3860 ± 0.00000
Day 73.3860 ± 0.00000
Day 103.3860 ± 0.00000
SecondaryPeriod 1: Absolute Values for Urinalysis Parameter: pH

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Time frame:
Day 9
Reported as:
Mean · pH
Period 1: Absolute Values for Urinalysis Parameter: pH
pHDolutegravir 50 mg
Period 1: Absolute Values for Urinalysis Parameter: pH5.88 ± 0.465
SecondaryPeriod 2: Absolute Values for Urinalysis Parameter: pH

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Time frame:
Day 7
Reported as:
Mean · pH
Period 2: Absolute Values for Urinalysis Parameter: pH
pHGSK3640254 200 mg
Period 2: Absolute Values for Urinalysis Parameter: pH6.00 ± 0.548
SecondaryPeriod 3: Absolute Values for Urinalysis Parameter: pH

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Time frame:
Days 4, 7 and 10
Reported as:
Mean · pH
Period 3: Absolute Values for Urinalysis Parameter: pH
pHDolutegravir 50 mg + GSK3640254 200 mg
Day 46.03 ± 0.591
Day 75.88 ± 0.387
Day 106.16 ± 0.473
SecondaryPeriod 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

Time frame:
Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Reported as:
Mean · Milliseconds
Period 1: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB
MillisecondsDolutegravir 50 mg
PR Interval: Day 1, 2 hours159.1 ± 14.42
PR Interval: Day 1, 4 hours161.3 ± 16.51
PR Interval: Day 5, Pre-dose164.3 ± 14.87
PR Interval: Day 5, 2 hours160.9 ± 11.34
PR Interval: Day 5, 4 hours161.5 ± 12.66
QRS Duration: Day 1, 2 hours95.2 ± 9.59
QRS Duration: Day 1, 4 hours94.7 ± 10.90
QRS Duration: Day 5, Pre-dose92.6 ± 8.39
QRS Duration: Day 5, 2 hours94.2 ± 10.78
QRS Duration: Day 5, 4 hours94.0 ± 9.26
QT Interval: Day 1, 2 hours386.4 ± 16.06
QT Interval: Day 1, 4 hours401.8 ± 19.94
QT Interval: Day 5, Pre-dose385.1 ± 13.96
QT Interval: Day 5, 2 hours375.6 ± 11.46
QT Interval: Day 5, 4 hours393.1 ± 18.80
QTcF Interval: Day 1, 2 hours391.6 ± 11.37
QTcF Interval: Day 1, 4 hours395.0 ± 12.90
QTcF Interval: Day 5, Pre-dose389.5 ± 10.92
QTcF Interval: Day 5, 2 hours388.6 ± 14.47
QTcF Interval: Day 5, 4 hours392.7 ± 14.11
QTcB Interval: Day 1, 2 hours393.1 ± 15.31
QTcB Interval: Day 1, 4 hours390.2 ± 16.01
QTcB Interval: Day 5, Pre-dose390.9 ± 14.91
QTcB Interval: Day 5, 2 hours394.2 ± 21.59
QTcB Interval: Day 5, 4 hours391.7 ± 19.71
SecondaryPeriod 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

Time frame:
Day 1: 2 hours, 4 hours; Day 5: Pre-dose, 2 hours and 4 hours
Reported as:
Mean · Milliseconds
Period 2: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB
MillisecondsGSK3640254 200 mg
PR Interval: Day 1, 2 hours165.1 ± 15.46
PR Interval: Day 1, 4 hours165.4 ± 14.32
PR Interval: Day 5, Pre-dose166.3 ± 16.89
PR Interval: Day 5, 2 hours165.0 ± 19.90
PR Interval: Day 5, 4 hours162.0 ± 13.64
QRS Duration: Day 1, 2 hours94.1 ± 9.66
QRS Duration: Day 1, 4 hours92.9 ± 9.20
QRS Duration: Day 5, Pre-dose94.3 ± 10.12
QRS Duration: Day 5, 2 hours93.9 ± 9.00
QRS Duration: Day 5, 4 hours94.7 ± 8.51
QT Interval: Day 1, 2 hours381.8 ± 14.37
QT Interval: Day 1, 4 hours394.4 ± 19.18
QT Interval: Day 5, Pre-dose392.6 ± 23.20
QT Interval: Day 5, 2 hours382.6 ± 17.13
QT Interval: Day 5, 4 hours396.0 ± 21.45
QTcF Interval: Day 1, 2 hours390.0 ± 13.74
QTcF Interval: Day 1, 4 hours394.4 ± 12.38
QTcF Interval: Day 5, Pre-dose397.9 ± 14.64
QTcF Interval: Day 5, 2 hours395.0 ± 14.70
QTcF Interval: Day 5, 4 hours401.5 ± 12.66
QTcB Interval: Day 1, 2 hours393.3 ± 18.57
QTcB Interval: Day 1, 4 hours393.4 ± 18.53
QTcB Interval: Day 5, Pre-dose399.2 ± 16.61
QTcB Interval: Day 5, 2 hours400.7 ± 20.02
QTcB Interval: Day 5, 4 hours403.2 ± 13.41
SecondaryPeriod 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB

Twelve-lead ECG were obtained to measure PR Interval, QRS Duration, QT Interval, QTcF Interval and QTcB Interval. Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes.

Time frame:
Day 1: 2 hours, 4 hours; Days 4, 5 and 7: Pre-dose, 2 hours and 4 hours; Day 10
Reported as:
Mean · Milliseconds
Period 3: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF, QTcB
MillisecondsDolutegravir 50 mg + GSK3640254 200 mg
PR Interval: Day 1, 2 hours167.9 ± 13.86
PR Interval: Day 1, 4 hours164.1 ± 15.12
PR Interval: Day 4, Pre-dose165.6 ± 16.02
PR Interval: Day 4, 2 hours166.9 ± 15.67
PR Interval: Day 4, 4 hours163.1 ± 15.13
PR Interval: Day 5, Pre-dose164.6 ± 18.30
PR Interval: Day 5, 2 hours162.8 ± 12.71
PR Interval: Day 5, 4 hours163.3 ± 14.96
PR Interval: Day 7, Pre-dose169.6 ± 17.47
PR Interval: Day 7, 2 hours165.0 ± 15.69
PR Interval: Day 7, 4 hours165.6 ± 15.00
PR Interval: Day 10168.3 ± 17.14
QRS Duration: Day 1, 2 hours95.9 ± 10.49
QRS Duration: Day 1, 4 hours92.8 ± 8.76
QRS Duration: Day 4, Pre-dose96.8 ± 9.41
QRS Duration: Day 4, 2 hours93.5 ± 8.21
QRS Duration: Day 4, 4 hours95.3 ± 8.79
QRS Duration: Day 5, Pre-dose96.6 ± 9.77
QRS Duration: Day 5, 2 hours96.1 ± 11.66
QRS Duration: Day 5, 4 hours94.3 ± 9.56
QRS Duration: Day 7, Pre-dose95.4 ± 9.44
QRS Duration: Day 7, 2 hours95.1 ± 9.52
QRS Duration: Day 7, 4 hours94.4 ± 9.30
QRS Duration: Day 1096.5 ± 9.14
QT Interval: Day 1, 2 hours380.0 ± 12.90
QT Interval: Day 1, 4 hours392.3 ± 16.39
QT Interval: Day 4, Pre-dose389.2 ± 18.65
QT Interval: Day 4, 2 hours376.6 ± 18.49
QT Interval: Day 4, 4 hours395.3 ± 17.89
QT Interval: Day 5, Pre-dose386.4 ± 18.49
QT Interval: Day 5, 2 hours380.9 ± 13.91
QT Interval: Day 5, 4 hours391.8 ± 20.53
QT Interval: Day 7, Pre-dose391.0 ± 21.99
QT Interval: Day 7, 2 hours382.3 ± 13.85
QT Interval: Day 7, 4 hours395.8 ± 20.94
QT Interval: Day 10392.9 ± 14.54
QTcF Interval: Day 1, 2 hours392.7 ± 11.45
QTcF Interval: Day 1, 4 hours399.7 ± 10.37
QTcF Interval: Day 4, Pre-dose395.8 ± 13.94
QTcF Interval: Day 4, 2 hours390.6 ± 12.33
QTcF Interval: Day 4, 4 hours401.2 ± 13.55
QTcF Interval: Day 5, Pre-dose399.2 ± 14.92
QTcF Interval: Day 5, 2 hours394.3 ± 12.83
QTcF Interval: Day 5, 4 hours401.7 ± 11.91
QTcF Interval: Day 7, Pre-dose395.1 ± 12.91
QTcF Interval: Day 7, 2 hours393.7 ± 12.69
QTcF Interval: Day 7, 4 hours396.8 ± 13.47
QTcF Interval: Day 10394.8 ± 13.08
QTcB Interval: Day 1, 2 hours398.4 ± 15.81
QTcB Interval: Day 1, 4 hours402.0 ± 15.46
QTcB Interval: Day 4, Pre-dose398.4 ± 17.82
QTcB Interval: Day 4, 2 hours394.0 ± 21.41
QTcB Interval: Day 4, 4 hours403.1 ± 17.67
QTcB Interval: Day 5, Pre-dose405.1 ± 23.00
QTcB Interval: Day 5, 2 hours400.1 ± 18.05
QTcB Interval: Day 5, 4 hours405.9 ± 16.27
QTcB Interval: Day 7, Pre-dose396.6 ± 17.50
QTcB Interval: Day 7, 2 hours398.9 ± 21.21
QTcB Interval: Day 7, 4 hours396.0 ± 18.10
QTcB Interval: Day 10394.8 ± 18.39
SecondaryPeriod 1: Absolute Values for SBP and DBP

SBP and DBP were measured in the semi-recumbent position with a completely automated device.

Time frame:
Days 2, 3, 4 and 5
Reported as:
Mean · Millimeters of mercury
Period 1: Absolute Values for SBP and DBP
Millimeters of mercuryDolutegravir 50 mg
SBP: Day 2118.8 ± 8.57
SBP: Day 3114.9 ± 8.09
SBP: Day 4119.0 ± 9.81
SBP: Day 5109.1 ± 7.16
DBP: Day 276.1 ± 6.53
DBP: Day 372.7 ± 8.32
DBP: Day 474.1 ± 8.58
DBP: Day 569.2 ± 9.77
SecondaryPeriod 2: Absolute Values for SBP and DBP

SBP and DBP were measured in the semi-recumbent position with a completely automated device.

Time frame:
Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Millimeters of mercury
Period 2: Absolute Values for SBP and DBP
Millimeters of mercuryGSK3640254 200 mg
SBP: Day 2115.8 ± 7.15
SBP: Day 3115.3 ± 7.57
SBP: Day 4117.1 ± 8.74
SBP: Day 5113.6 ± 7.35
SBP: Day 6113.9 ± 8.29
SBP: Day 7114.6 ± 5.73
DBP: Day 269.6 ± 8.50
DBP: Day 371.1 ± 7.65
DBP: Day 469.6 ± 5.24
DBP: Day 568.8 ± 6.49
DBP: Day 670.3 ± 7.02
DBP: Day 770.4 ± 6.65
SecondaryPeriod 3: Absolute Values for SBP and DBP

SBP and DBP were measured in the semi-recumbent position with a completely automated device.

Time frame:
Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Millimeters of mercury
Period 3: Absolute Values for SBP and DBP
Millimeters of mercuryDolutegravir 50 mg + GSK3640254 200 mg
SBP: Day 2115.8 ± 8.12
SBP: Day 3112.5 ± 5.81
SBP: Day 4112.6 ± 6.11
SBP: Day 5119.4 ± 19.70
SBP: Day 6114.4 ± 7.45
SBP: Day 7113.8 ± 8.13
SBP: Day 8113.9 ± 6.72
SBP: Day 9113.6 ± 7.67
SBP: Day 10111.6 ± 6.38
SBP: Day 11112.4 ± 7.69
DBP: Day 269.0 ± 6.46
DBP: Day 367.7 ± 6.52
DBP: Day 468.9 ± 6.33
DBP: Day 574.4 ± 21.90
DBP: Day 669.2 ± 8.27
DBP: Day 770.6 ± 5.78
DBP: Day 869.5 ± 9.34
DBP: Day 969.8 ± 5.98
DBP: Day 1070.0 ± 5.14
DBP: Day 1167.7 ± 4.32
SecondaryPeriod 1: Absolute Values for Pulse Rate

Pulse rate was measured in the semi-recumbent position with a completely automated device.

Time frame:
Days 2, 3, 4 and 5
Reported as:
Mean · Beats per minute
Period 1: Absolute Values for Pulse Rate
Beats per minuteDolutegravir 50 mg
Day 267.8 ± 8.47
Day 366.8 ± 6.68
Day 470.1 ± 10.57
Day 566.4 ± 8.21
SecondaryPeriod 2: Absolute Values for Pulse Rate

Pulse rate was measured in the semi-recumbent position with a completely automated device.

Time frame:
Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Beats per minute
Period 2: Absolute Values for Pulse Rate
Beats per minuteGSK3640254 200 mg
Day 268.3 ± 9.75
Day 369.7 ± 8.65
Day 469.1 ± 8.21
Day 568.5 ± 11.14
Day 668.1 ± 8.88
Day 767.0 ± 8.95
SecondaryPeriod 3: Absolute Values for Pulse Rate

Pulse rate was measured in the semi-recumbent position with a completely automated device.

Time frame:
Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Beats per minute
Period 3: Absolute Values for Pulse Rate
Beats per minuteDolutegravir 50 mg + GSK3640254 200 mg
Day 268.4 ± 9.79
Day 368.9 ± 8.63
Day 466.9 ± 9.26
Day 569.8 ± 10.57
Day 667.9 ± 10.12
Day 764.6 ± 8.02
Day 869.0 ± 12.02
Day 965.9 ± 10.12
Day 1063.8 ± 8.53
Day 1168.4 ± 12.27
SecondaryPeriod 1: Absolute Values for Respiratory Rate

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Time frame:
Days 2, 3, 4 and 5
Reported as:
Mean · Breaths per minute
Period 1: Absolute Values for Respiratory Rate
Breaths per minuteDolutegravir 50 mg
Day 213.5 ± 1.37
Day 314.6 ± 2.16
Day 412.9 ± 1.78
Day 513.6 ± 2.22
SecondaryPeriod 2: Absolute Values for Respiratory Rate

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Time frame:
Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Breaths per minute
Period 2: Absolute Values for Respiratory Rate
Breaths per minuteGSK3640254 200 mg
Day 2, n=1613.6 ± 0.81
Day 3, n=1614.5 ± 2.00
Day 4, n=1613.5 ± 1.15
Day 5, n=1515.3 ± 2.09
Day 6, n=1613.8 ± 2.52
Day 7, n=1614.3 ± 2.18
SecondaryPeriod 3: Absolute Values for Respiratory Rate

Respiratory rate was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Time frame:
Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Breaths per minute
Period 3: Absolute Values for Respiratory Rate
Breaths per minuteDolutegravir 50 mg + GSK3640254 200 mg
Day 215.0 ± 2.42
Day 314.1 ± 1.54
Day 413.9 ± 2.96
Day 513.1 ± 1.45
Day 614.3 ± 2.05
Day 713.9 ± 1.86
Day 815.0 ± 1.03
Day 913.3 ± 3.00
Day 1015.0 ± 1.79
Day 1116.4 ± 1.31
SecondaryPeriod 1: Absolute Values for Body Temperature

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Time frame:
Days 2, 3, 4 and 5
Reported as:
Mean · Degrees Celsius
Period 1: Absolute Values for Body Temperature
Degrees CelsiusDolutegravir 50 mg
Day 236.36 ± 0.303
Day 336.26 ± 0.287
Day 436.21 ± 0.361
Day 536.43 ± 0.270
SecondaryPeriod 2: Absolute Values for Body Temperature

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Time frame:
Days 2, 3, 4, 5, 6 and 7
Reported as:
Mean · Degrees Celsius
Period 2: Absolute Values for Body Temperature
Degrees CelsiusGSK3640254 200 mg
Day 236.26 ± 0.339
Day 336.15 ± 0.361
Day 436.21 ± 0.318
Day 536.35 ± 0.306
Day 636.28 ± 0.309
Day 736.28 ± 0.394
SecondaryPeriod 3: Absolute Values for Body Temperature

Body temperature was measured in the semi-recumbent position after at least 5 minutes of rest for the participant in a quiet setting without distractions.

Time frame:
Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Mean · Degrees Celsius
Period 3: Absolute Values for Body Temperature
Degrees CelsiusDolutegravir 50 mg + GSK3640254 200 mg
Day 236.33 ± 0.284
Day 336.22 ± 0.369
Day 436.42 ± 0.412
Day 536.40 ± 0.405
Day 636.37 ± 0.366
Day 736.46 ± 0.371
Day 836.28 ± 0.451
Day 936.30 ± 0.337
Day 1036.37 ± 0.294
Day 1136.53 ± 0.307
SecondaryPeriod 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 for GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Median · Hours
Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 for GSK3640254 Arm
HoursGSK3640254 200 mg
Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 for GSK3640254 Arm5.000 (3.50 to 8.00)
SecondaryPeriod 3: Tmax of GSK3640254 for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Median · Hours
Period 3: Tmax of GSK3640254 for Dolutegravir + GSK3640254 Arm
HoursDolutegravir 50 mg + GSK3640254 200 mg
Period 3: Tmax of GSK3640254 for Dolutegravir + GSK3640254 Arm5.000 (3.50 to 8.00)
SecondaryPeriod 2: Apparent Terminal Phase Half-life (T1/2) of GSK3640254 for GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Data could not be determined due to limited sampling points after final dosing (during elimination phase). An accurate determination of GSK3640254 half-life would require sampling up to 3 times half-life (3 \* approximately 24 hours). However sampling in Period 2 was performed up to only 24 hours post-dose.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours
Period 2: Apparent Terminal Phase Half-life (T1/2) of GSK3640254 for GSK3640254 Arm
HoursGSK3640254 200 mg
Period 2: Apparent Terminal Phase Half-life (T1/2) of GSK3640254 for GSK3640254 ArmNA ± NA
SecondaryPeriod 3: T1/2 of GSK3640254 for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK3640254. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours
Period 3: T1/2 of GSK3640254 for Dolutegravir + GSK3640254 Arm
HoursDolutegravir 50 mg + GSK3640254 200 mg
Period 3: T1/2 of GSK3640254 for Dolutegravir + GSK3640254 Arm23.417 ± 15.0
SecondaryPeriod 1: Tmax of Dolutegravir for Dolutegravir Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Median · Hours
Period 1: Tmax of Dolutegravir for Dolutegravir Arm
HoursDolutegravir 50 mg
Period 1: Tmax of Dolutegravir for Dolutegravir Arm3.000 (1.00 to 4.50)
SecondaryPeriod 3: Tmax of Dolutegravir for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Median · Hours
Period 3: Tmax of Dolutegravir for Dolutegravir + GSK3640254 Arm
HoursDolutegravir 50 mg + GSK3640254 200 mg
Period 3: Tmax of Dolutegravir for Dolutegravir + GSK3640254 Arm3.000 (1.00 to 4.50)
SecondaryPeriod 1: T1/2 of Dolutegravir for Dolutegravir Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 5: Pre-dose, 1, 1.5, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours
Period 1: T1/2 of Dolutegravir for Dolutegravir Arm
HoursDolutegravir 50 mg
Period 1: T1/2 of Dolutegravir for Dolutegravir Arm14.492 ± 11.8
SecondaryPeriod 3: T1/2 of Dolutegravir for Dolutegravir + GSK3640254 Arm

Blood samples were collected at the indicated time points for pharmacokinetic analysis of dolutegravir. The pharmacokinetic parameters were calculated by standard non-compartmental analysis.

Time frame:
Day 7: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hours
Period 3: T1/2 of Dolutegravir for Dolutegravir + GSK3640254 Arm
HoursDolutegravir 50 mg + GSK3640254 200 mg
Period 3: T1/2 of Dolutegravir for Dolutegravir + GSK3640254 Arm14.690 ± 12.1

Adverse events

Collected over Non-SAEs and SAEs were collected from start of the study treatment up to Day 27. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dolutegravir 50 mg0/16 (0%)0/16 (0%)1/16 (6.3%)
GSK3640254 200 mg0/16 (0%)0/16 (0%)3/16 (18.8%)
Dolutegravir 50 mg + GSK3640254 200 mg0/16 (0%)0/16 (0%)2/16 (12.5%)
Most frequent other events
Most frequent other events
EventDolutegravir 50 mgGSK3640254 200 mgDolutegravir 50 mg + GSK3640254 200 mg
DermatitisSkin and subcutaneous tissue disorders0/160/161/16
Dermatitis contactSkin and subcutaneous tissue disorders0/160/161/16
Keratosis pilarisSkin and subcutaneous tissue disorders0/161/160/16
Medical device site dermatitisGeneral disorders0/161/161/16
FatigueGeneral disorders0/160/161/16
Ear pruritusEar and labyrinth disorders0/160/161/16
Skin abrasionInjury, poisoning and procedural complications1/160/160/16
ArthralgiaMusculoskeletal and connective tissue disorders0/161/160/16
AnxietyPsychiatric disorders0/161/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dolutegravir/GSK3640254/Dolutegravir+GSK3640254
Mean36.7 ± 10.66
Sex: Female, Male
Sex: Female, Male(Participants)Dolutegravir/GSK3640254/Dolutegravir+GSK3640254
Female1
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dolutegravir/GSK3640254/Dolutegravir+GSK3640254
Asian - East Asian Heritage1
Asian - South East Asian Heritage1
Black or African American3
White - White/Caucasian/European Heritage11
08

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744, United States
09

References and documents

Publications

  • Pene Dumitrescu T, Joshi SR, Xu J, Greene TJ, Johnson M, Butcher L, Zimmerman E, Webster L, Pham TT, Lataillade M, Min S. Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults. Br J Clin Pharmacol. 2021 Sep;87(9):3501-3507. doi: 10.1111/bcp.14759. Epub 2021 Mar 4. PubMed 33533507 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Mar 2019, 2 months.

Results were first posted in Mar 2020, 11 months after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 2 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2019
First posted
Jan 25, 2019
StartActual
Jan 23, 2019
Primary completionActual
Mar 30, 2019
CompletionActual
Apr 10, 2019
Results first posted
Mar 19, 2020
Last update
Mar 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03816696
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jan 25, 2019
Start date
Jan 23, 2019
Primary completion
Mar 30, 2019
Completion
Apr 10, 2019
Results posted
Mar 19, 2020
Last update
Mar 19, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK3640254 · Dolutegravir

Start the discussion